glucose
baxter healthcare limited - glucose monohydrate - solution for infusion - 10 %w/v - carbohydrates
glucose
fresenius kabi limited - glucose anhydrous - solution for infusion - 10 %w/w - carbohydrates
glucose 5% w/v solution for infusion
fresenius kabi limited - glucose anhydrous - solution for infusion - 5 percent weight/volume - solutions for parenteral nutrition; carbohydrates
glucose
maco pharma (uk) ltd - glucose monohydrate - solution for infusion - 5 %w/v - electrolytes with carbohydrates
glucose
fresenius kabi limited - glucose anhydrous - solution for infusion - 5 %w/w - carbohydrates
glucose 5% w/v intravenous infusion
baxter healthcare limited - glucose monohydrate - solution for infusion - 5.0 anhyd %w/v - carbohydrates
glucose injection bp minijet 50%w/v, solution for injection
international medication systems (uk) ltd - anhydrous glucose - solution for injection - 50 percent weight/volume - carbohydrates; glucose
sodium chloride 0.45% w/v and glucose 5.0% w/v solution for infusion bp
baxter healthcare limited - glucose, sodium chloride - solution for infusion - glucose 5 percent weight/volume ; sodium chloride 0.45 percent weight/volume - blood substitutes and perfusion solutions
glucose 5g/100 ml b. braun vet care solution for infusion for cattle, horses, sheep, goats, pigs, dogs and cats
b. braun melsungen ag. - glucose monohydrate - solution for infusion - 5 grams/100 millilitres - i.v. solutions - cats, cattle, dogs, goats, horses, pigs, sheep - electrolytes
zoledronic acid accord zoledronic acid 4mg/5ml concentrated injection vial
accord healthcare pty ltd - zoledronic acid monohydrate, quantity: 4.264 mg (equivalent: zoledronic acid, qty 4 mg) - injection, concentrated - excipient ingredients: sodium citrate dihydrate; mannitol; water for injections - zoledronic acid accord is indicated:,for the prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,for treatment of tumour-induced hypercalcaemia.,as an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.